John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 8,694 shares at $6.03 ($53K) on 2022-04-25, disclosed to the SEC on 2022-04-27.
Scheduled sale ($53k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.03 | 2,036 | $12K | 23.4% |
| 2 | $6.07 | 2,147 | $13K | 24.8% |
| 3 | $6.03 | 4,511 | $27K | 51.8% |
| Total | $6.04 avg | 8,694 | $53K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |
| FUSN | SELL | 2022-04-01 | $2K | — | Filing → |